They ask not to take these cold medicines due to risk of heart attack

healthy

this National Agency for the Safety of Medicines and Health Products (ANSM) A campaign has been launched to advise against the use of some cold medicines that have vasoconstrictive effects. Christelle Ratignier Carbonneil, the organization’s director general, gave the following advice to Le Parisien: “I want to tell the French: don’t use them anymore!”

Cold medicines may increase heart attack risk

Drugs that increase the risk of vascular and brain accidents, such as myocardial infarction, are awaiting bans in the European Union (EU).Carbonnier clarified that they were Tablets or nasal spray containing pseudoephedrine.

“Despite the measures that have been put in place, cases are still occurring. Recent data continues to show serious impactseven though the common cold is a benign disease,” he said.

France’s National Medicines Agency noted in a note that “the risk is very slight, but these events can occur regardless of the dose and duration of treatment. Despite the actions that have been taken, the seriousness of these incidents and the persistence of cases, Related to the non-essential nature of vasoconstrictorscausing ANSM to recommend against its use.

In France, These drugs are sold under the following brand names: Activated Rhume, Dli rhume, Humex Rhume, Nurofen Rhume, Rhinadvil Rhume Ibuprofène/Pseudoéphédrine and Rhinadvilcaps Rhume Ibuprofène/Pseudoéphédrine.

The EU began a reassessment of pseudoephedrine last February at the request of French regulators.Meanwhile, several French health organizations have joined ANSM’s decision, continuing Data from the medical literature and pharmacovigilance Recently acquired.

Research into these cold medicines began with the release of new data on a “small number” of cases in which pseudoephedrine drugs were used.These patients appear Reversible cerebral vasoconstriction syndrome (RCVS) or posterior reversible encephalopathy syndrome (PRES).

Now the European Medicines Agency (EMA) is looking into whether the risks of using these drugs may cause more problems than they solve. The results will be sent to the Committee for Medicinal Products for Human Use, which will issue an opinion. In order for changes to the provisions to take effect, the European Commission must make a legally binding decision: Applies to all EU member states.